Compare Stocks: TCRT, BCDA, TPST, and BIVI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.15 -1.7%	$0.98	$0.75 ▼ $2.29	$17.71M	0.48	265,131 shs	158,989 shs
BIVI BioVie	$2.16 -1.4%	$1.71	$0.82 ▼ $3.79	$18.51M	0.6	14.01 million shs	483,161 shs
TCRT Alaunos Therapeutics	$1.61 -3.3%	$1.98	$1.55 ▼ $4.59	$4.22M	-1	11,157 shs	35,632 shs
TPST Tempest Therapeutics	$1.06 -1.9%	$1.03	$0.84 ▼ $12.23	$17.86M	-1.72	286,127 shs	62,265 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	-1.68%	+20.98%	+49.71%	+25.81%	-39.69%
BIVI BioVie	+3.79%	+17.74%	+64.66%	+54.23%	+35.19%
TCRT Alaunos Therapeutics	-6.54%	-7.78%	-12.63%	-41.75%	-12.17%
TPST Tempest Therapeutics	0.00%	+5.88%	+24.00%	-29.41%	-89.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.15 -1.7%	$0.98	$0.75 ▼ $2.29	$17.71M	0.48	265,131 shs	158,989 shs
BIVI BioVie	$2.16 -1.4%	$1.71	$0.82 ▼ $3.79	$18.51M	0.6	14.01 million shs	483,161 shs
TCRT Alaunos Therapeutics	$1.61 -3.3%	$1.98	$1.55 ▼ $4.59	$4.22M	-1	11,157 shs	35,632 shs
TPST Tempest Therapeutics	$1.06 -1.9%	$1.03	$0.84 ▼ $12.23	$17.86M	-1.72	286,127 shs	62,265 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	-1.68%	+20.98%	+49.71%	+25.81%	-39.69%
BIVI BioVie	+3.79%	+17.74%	+64.66%	+54.23%	+35.19%
TCRT Alaunos Therapeutics	-6.54%	-7.78%	-12.63%	-41.75%	-12.17%
TPST Tempest Therapeutics	0.00%	+5.88%	+24.00%	-29.41%	-89.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	2.00	Hold	$25.00	2,073.91% Upside
BIVI BioVie	1.00	Sell	N/A	N/A
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A
TPST Tempest Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, BCDA, TPST, and BIVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	BIVI BioVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	TPST Tempest Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/9/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
5/29/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	290.18	N/A	N/A	$0.18 per share	6.39
BIVI BioVie	N/A	N/A	N/A	N/A	$1.22 per share	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.26 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
BIVI BioVie	-$22.07M	-$3.15	N/A	N/A	N/A	N/A	-126.02%	-108.88%	11/9/2026 (Estimated)
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-232.60%	-158.99%	N/A
TPST Tempest Therapeutics	-$26.26M	-$4.28	N/A	N/A	N/A	N/A	-576.56%	-134.99%	11/4/2026 (Estimated)

Latest TCRT, BCDA, TPST, and BIVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A
8/13/2026	Q2 2026	TPST Tempest Therapeutics	-$0.30	-$0.34	-$0.04	-$0.34	N/A	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A
8/12/2026	Q4 2026	BIVI BioVie	-$0.52	-$0.70	-$0.18	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	2.09	2.09
BIVI BioVie	N/A	3.59	3.59
TCRT Alaunos Therapeutics	N/A	0.77	0.77
TPST Tempest Therapeutics	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
BIVI BioVie	4.59%
TCRT Alaunos Therapeutics	27.72%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	17.40%
BIVI BioVie	0.90%
TCRT Alaunos Therapeutics	16.14%
TPST Tempest Therapeutics	36.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	40	15.14 million	12.51 million	Optionable
BIVI BioVie	10	8.45 million	8.38 million	No Data
TCRT Alaunos Therapeutics	40	2.54 million	2.13 million	No Data
TPST Tempest Therapeutics	20	16.54 million	10.55 million	No Data

TCRT, BCDA, TPST, and BIVI Headlines

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

August 13, 2026 | quiverquant.comQ

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | finanznachrichten.de

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

July 21, 2026 | quiverquant.comQ

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | globenewswire.com

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial

July 15, 2026 | quiverquant.comQ

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026 | globenewswire.com

Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | quiverquant.comQ

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | globenewswire.com

Tempest Therapeutics Announces Resignation of Board Director

May 29, 2026 | tipranks.com

Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants

May 29, 2026 | quiverquant.comQ

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026 | globenewswire.com

Tempest Therapeutics Announces Multiple Board Director Resignations

May 22, 2026 | tipranks.com

Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026 | finanznachrichten.de

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026 | globenewswire.com

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026 | globenewswire.com

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 22, 2026 | globenewswire.com

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026 | globenewswire.com

New Strong Buy Stocks for April 10th

April 10, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCDA, TPST, and BIVI Company Descriptions

BioCardia NASDAQ:BCDA

$1.15 -0.02 (-1.71%)

As of 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

BioVie NASDAQ:BIVI

$2.16 -0.03 (-1.37%)

As of 04:00 PM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Alaunos Therapeutics NASDAQ:TCRT

$1.60 -0.06 (-3.31%)

As of 03:59 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Tempest Therapeutics NASDAQ:TPST

$1.06 -0.02 (-1.85%)

As of 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, BCDA, TPST, and BIVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, BCDA, TPST, and BIVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, BCDA, TPST, and BIVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCDA, TPST, and BIVI Company Descriptions

BioCardia NASDAQ:BCDA

BioVie NASDAQ:BIVI

Alaunos Therapeutics NASDAQ:TCRT

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, BCDA, TPST, and BIVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, BCDA, TPST, and BIVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, BCDA, TPST, and BIVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCDA, TPST, and BIVI Company Descriptions

BioCardia NASDAQ:BCDA

BioVie NASDAQ:BIVI

Alaunos Therapeutics NASDAQ:TCRT

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools